PepGen Inc. PEPG 深 滬
等待開盤 08-20 09:30:00 美东时间
1.2692
-0.031
-2.37%
華盛通- 最 高1.3457
- 今 開1.31
- 成交量 7.22万股
- 最 低 1.23
- 昨 收 1.30
- 總市值 4152.94万
- 52周最高 10.055
- 市盈率 靜 --
- 換手率 0.22%
- 52周最低 0.8801
- 委 比 50.83%
- 總股本 3272.09万
- 歷史最高 20.00
- 量 比 0.11
- 振 幅 8.90%
- 歷史最低 0.8801
- 每 手 1
- 風險率 4.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PepGen Q2 EPS $(0.70) Beats $(0.87) Estimate
PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.87) by 19.26 percent. This is a 19.54 percent increase over losses of $(0.87) per share from the same
08-07 20:08
PEPG Lawsuit Alert! Class Action Lawsuit Against PepGen Inc.
Aclass actionlawsuit was filed againstPepGen Inc. ($PEPG) by ...
07-17 23:24
Why Rent the Runway Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Shares of Rent the Runway, Inc. (NASDAQ:RENT) rose sharply in today's pre-marke...
06-06 18:52
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate
PepGen ends Duchenne drug program after weak Phase 2 results, pivots to DM1 treatment showing early signs of splicing correction and safety.
05-29 21:19
HC Wainwright & Co. Maintains Buy on PepGen, Lowers Price Target to $8
HC Wainwright & Co. analyst Andrew Fein maintains PepGen (NASDAQ:PEPG) with a Buy and lowers the price target from $14 to $8.
05-29 21:13
PepGen Shifts Focus To DM1 Program Following CONNECT1-EDO51 Dystrophin Data
– PGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs –– PGN-EDO51 at 10 mg/kg was generally well tolerated; all treatment-related adverse events
05-29 04:12
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
HC Wainwright & Co. Maintains Buy on PepGen, Lowers Price Target to $14
HC Wainwright & Co. analyst Andrew Fein maintains PepGen (NASDAQ:PEPG) with a Buy and lowers the price target from $16 to $14.
05-09 21:29
PepGen Q1 EPS $(0.92) Misses $(0.71) Estimate
PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.71) by 29.58 percent. This is a 46.03 percent decrease over losses of $(0.63) per share from the same
05-08 20:02
